INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.42
-0.11 (-0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.53
Open17.39
Bid15.91 x 800
Ask17.40 x 2200
Day's Range16.92 - 17.72
52 Week Range11.31 - 33.13
Volume646,686
Avg. Volume1,206,547
Market Cap1.554B
Beta (3Y Monthly)3.69
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on October 1, 2019 to purchase an aggregate 46,170 shares of Insmed common stock at an exercise price of $17.20 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Insmed to Present at Two September Conferences
    PR Newswire

    Insmed to Present at Two September Conferences

    Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

  • Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update
    PR Newswire

    Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update

    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019-- --Marketing Authorization Application for ARIKAYCE Submitted and Validated by ...

  • Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019
    PR Newswire

    Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019

    BRIDGEWATER, N.J. , July 25, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today ...

  • Insmed Announces Closing of Public Offering of Common Stock
    PR Newswire

    Insmed Announces Closing of Public Offering of Common Stock

    BRIDGEWATER, N.J., June 26, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) today announced the closing on June 25, 2019 of the issuance of an additional 1,442,307 shares of common stock pursuant to the full exercise of the underwriter's overallotment option related to the previously announced public offering of its common stock. The underwriters were granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company's Chairman and Chief Executive Officer at a public offering price of $26.00 per share. The net proceeds to the Company from the sale of the additional shares, after deducting underwriting discounts and commissions but before expenses, were approximately $25.6 million.  The Company did not receive any proceeds from the sale of Mr. Lewis' shares.

  • Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire

    Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., June 6, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes on Thursday, June 13, 2019 at 8:00 a.m. PDT. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed Announces Pricing of Public Offering of Common Stock
    PR Newswire

    Insmed Announces Pricing of Public Offering of Common Stock

    BRIDGEWATER, N.J., May 21, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of $26.00 per share before underwriting discounts and commissions. Gross proceeds from the offering of these shares, before deducting underwriting discounts and commissions, are expected to be approximately $250.0 million.  The underwriters have been granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company's Chairman and Chief Executive Officer.

  • Insmed Announces Proposed Public Offering of Common Stock
    PR Newswire

    Insmed Announces Proposed Public Offering of Common Stock

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $25.5 million of its common stock at the public offering price, less the underwriting discounts and commissions. William H. Lewis, the Company's Chairman and Chief Executive Officer, intends to grant the underwriters a 30-day option to purchase up to $12 million of Insmed common stock held by Mr. Lewis also at the public offering price.

  • New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
    PR Newswire

    New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease, demonstrating that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.

  • Insmed Reports First Quarter 2019 Financial Results and Provides Business Update
    PR Newswire

    Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

    -- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 -- -- Company Raises Full-Year 2019 ARIKAYCE Revenue Guidance to Range of $90 Million ...

  • Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019
    PR Newswire

    Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

    BRIDGEWATER, N.J., April 30, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2019 financial results on Tuesday, May 7, 2019. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, May 7, 2019 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 6243203.

  • Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
    PR Newswire

    Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio

    BRIDGEWATER, N.J., April 9, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension). The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy. This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and the second with an expiry date of May 15, 2035.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
    PR Newswire

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch

    BRIDGEWATER, N.J., April 8, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary net product sales for the first quarter of 2019.  ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. "We continue to be very pleased with the U.S. launch progress of ARIKAYCE and the positive feedback received from the refractory MAC lung disease community," said Will Lewis, Chairman and Chief Executive Officer of Insmed.

  • Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference
    PR Newswire

    Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE® (amikacin liposome inhalation suspension) in Mycobacterium avium complex (MAC) lung disease will be presented as a late-breaker at the American Thoracic Society (ATS) International Conference, May 17-22, in Dallas. Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.

  • Insmed to Present at the H.C. Wainwright Global Life Sciences Conference
    PR Newswire

    Insmed to Present at the H.C. Wainwright Global Life Sciences Conference

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8, 2019 at 10:50 a.m. BST. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed Announces Management Changes
    PR Newswire

    Insmed Announces Management Changes

    BRIDGEWATER, N.J. , March 27, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

  • Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
    PR Newswire

    Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018-- --Company Provides Full-Year 2019 ARIKAYCE Revenue Guidance of $80 ...

  • Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference
    PR Newswire

    Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., Feb. 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Leerink Partners 8th Annual Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 3:30 p.m. ET. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.